MedTrace Logo

Neural Biomarkers of Clozapine Response

NCT03076346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2025-03-06

No results posted yet for this study

Summary

Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown. The overall goal of this study is to examine the functional neural circuitry that underlies successful treatment with clozapine, which may lead to the identification of biomarkers that will allow for more efficient use of clozapine, as well as additional treatment targets for patients with refractory illness.

Conditions

  • Schizophrenia
  • Treatment-resistant Schizophrenia
  • Schizoaffective Disorder

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076346 on ClinicalTrials.gov